ENYO Pharma Announces Completion of Series C Financing With Vesalius Biocapital and Continued Progress of Its ALPESTRIA-1 Clinical Phase 2 Study in Alport Syndrome Patients
LYON, France--(BUSINESS WIRE)--ENYO Pharma ('ENYO'), a clinical-stage biotechnology company focused on developing FXR agonists for the treatment of severe kidney diseases, today announced the smooth continuation of its Phase 2 ALPESTRIA-1 trial in 26 Alport syndrome patients. The topline results from the trial are on track for the fourth quarter of 2025. In parallel, ENYO has finalized its Series C financing round with a €6 million investment from Vesalius Biocapital IV, bringing the total Series C raise to €32 million.
The ongoing ALPESTRIA-1 study evaluates Vonafexor, a highly selective and oral FXR agonist, in patients with Alport syndrome, a rare genetic kidney disease with no approved therapy. The trial involves a 24-week ascending doses regimen followed by a 12-week off-treatment observation period. ALPESTRIA-1 was launched mid 2024 in 4 countries (US, F, SP and D) following Orphan Drug Designation from both the FDA and EMA.
The new funding from Vesalius Biocapital IV extends ENYO's cash runway through the second half of 2026 and enables the initiation of two new clinical programs:
A proof-of-concept trial in patients with Chronic Kidney Disease (CKD) grade 3 and concurrent F2/F3 MASH, building on the promising renal results from the previous Phase 2 LIVIFY clinical study;
A PK/PD head-to-head comparison of Vonafexor and its analog EYP651 in healthy subjects.
In addition, ENYO will continue to expand its preclinical portfolio, notably in Autosomal Dominant Polycystic Kidney Disease (ADPKD), where the Vonafexor franchise could offer a novel and disease-modifying approach.
' We are pleased with the continued progress of ALPESTRIA-1 and honored to welcome Vesalius Biocapital to our investor syndicate and Dr. Jean-Christophe Renondin as new Board member,' said Dr. Jacky Vonderscher, CEO of ENYO. ' This additional investment will allow us to accelerate the development of our FXR agonist pipeline in both rare and more prevalent kidney diseases. We share a common belief with Vesalius in the transformative potential of Vonafexor and EYP651 for patients suffering from inflammation- and fibrosis-driven renal conditions.'
' Vesalius Biocapital is excited to support ENYO as it progresses into the next phase of clinical development for Vonafexor and its analog EYP651, ' commented Dr. Jean-Christophe Renondin, Managing Partner at Vesalius Biocapital IV. ' There is an immense need for new treatments in kidney conditions such as Alport Syndrome and CKD. We believe Vonafexor has the potential to help these patients and make a meaningful impact on their lives. I look forward to working with ENYO's excellent leadership team to advance this promising therapeutic candidate.'
About ENYO Pharma:
ENYO is a clinical-stage biopharmaceutical company headquartered in Lyon (France) and developing proprietary drug candidates to improve quality of life and avoid end stage renal disease and dialysis/transplantation for patients with rare and common kidney diseases.
Since its inception ENYO collected extensive phase I/II clinical data through nine completed clinical studies with ca. 400 subjects.
ENYO is supported by a strong syndicate of global investors: OrbiMed, Morningside, AndEra, BPIFrance (InnoBio and Large Venture), Sofinnova Partners and Vesalius). For more information: ENYO Pharma
About Vesalius Biocapital:
Vesalius is a specialist life sciences venture capital investor, investing in companies in later stage companies in drug development, medical device diagnostic and e-health since 2007.
Vesalius Biocapital IV, launched in June 2023, targets first and best-in-class European life science companies in drug development and digital health.
Its investment portfolio is well balanced between drug development and non-drug development investments and committed to providing capital to science-backed innovation and ambitious entrepreneurs.
The team is based in Europe to explore investment opportunities and valuation potential for the portfolio. Managing Partners include Guy Geldhof, Dr Jean-Christophe Renondin and Stéphane Verdood.
https://www.vesaliusbiocapital-4.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Johnson Controls announces $9B increase to share repurchase program
The board of directors of Johnson Controls (JCI) has approved a $9B share repurchase authorization, adding to the $1.1B remaining as of the end of the second fiscal quarter under the share repurchase authorization previously approved in 2021. In implementing share repurchases, Johnson Controls may purchase shares in the open market or through a variety of methods as permitted by applicable securities laws and other legal requirements, including through the use of a Rule 10b5-1 plan, a tender offer or an accelerated share repurchase program or any combination of the foregoing. There exists no obligation under the share repurchase authorization to repurchase any particular amount of shares within any timeframe, and the manner, timing and amount of any purchase will be determined subject to an evaluation of the price of Johnson Controls' shares, general market conditions and other factors. Johnson Controls' authorization to repurchase shares does not have a set expiration date and may be amended, suspended or terminated at any time at Johnson Controls' discretion without prior notice. Johnson Controls currently expects to effect repurchases as redemptions pursuant to Article 3(d) of its Articles of Association.
Yahoo
3 hours ago
- Yahoo
Sombre Fundamentals Suggest General Mills Stock (GIS) is Stuck in a Value Trap
Not so long ago, General Mills (GIS) stock was synonymous with safety, defensiveness, and stability. The company consistently delivered results in line with market expectations, rewarding shareholders with a generous and growing dividend. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter The snacking category, once an exception among packaged food groups, seemed immune to changing eating habits and the rise of private-label brands. But things have taken a turn for the worse. Cereal and snack bar consumption has declined sharply due to growing structural headwinds, resulting in a contraction of General Mills' business. What remains solid, however, is the company's ability to generate value for shareholders above its cost of capital, which in theory still makes General Mills a defensive stock. Valuations at current levels also look attractive, offering some margin of safety. The problem is that the sustainability of these strengths is in question. When secular headwinds are at play, it doesn't matter much if fundamentals suggest a cushion or if valuations appear cheap—the stock is likely to continue drifting downward over time. That said, I see this as a potential value trap for investors hoping to be heroes with General Mills stock. For that reason, I hold a neutral view on GIS. U.S. consumers have been gradually changing their eating habits—and that's not just an opinion, it's a fact. The packaged foods sector has seen a decline in demand for snacks in recent years. A big part of this comes from the rapid rise in GLP-1 weight loss drugs and a new generation that's increasingly avoiding 'bad foods' in favor of a healthier lifestyle. Recent 2024 data shows that around 12% of American adults report having used a GLP-1 drug, with 6% currently using one. Some studies suggest that GLP-1 users significantly reduce their grocery store purchases by 6%, with a 11% drop in snack sales in the six months following adoption. This shift is already reflected in the financial results of packaged food companies, such as General Mills. Over the past three years, General Mills' revenue has grown at a CAGR of just 1.8%. While operating margins improved at a 4.9% compound annual growth rate (CAGR), free cash flow declined at an 8.7% CAGR, which is a concerning trend. In addition to these broad changes in consumer behavior, General Mills has been facing weak U.S. consumption trends due to market share losses in key categories, particularly to private-label brands from retailers such as Costco (COST) and Walmart (WMT). In its most recent earnings report, net sales totaled $4.8 billion, a 5% decline year over year, and fell short of analyst expectations. North American retail sales declined 7%, with a 6% drop in sales volume. Alongside softer demand, temporary pressures also played a role, including lower volumes in snacks and dry pet food. The pet segment declined 3% year over year, while international sales fell 4%, primarily due to foreign exchange headwinds and weaker results in key markets such as China and Brazil. As a result, General Mills revised its guidance for fiscal year 2025. The company now expects organic net sales to decline between 1.5% and 2%, compared to a previous forecast of flat to slightly positive growth (up to 1%). While General Mills' stock performance may appear underwhelming—hovering near the same levels it traded at over a decade ago—there are still compelling elements to its investment case. Despite a growth narrative that appears not just stalled but potentially in decline, the company continues to deliver strong returns on invested capital (ROIC). Over the past twelve months, General Mills generated $2.93 billion in NOPAT against $22.9 billion in invested capital, resulting in an ROIC of 12.8%. That figure aligns well with industry peers like Nestlé (NSRGY), Mondelez (MDLZ), and Kellogg's (KLG), and it comfortably exceeds the company's estimated cost of capital, highlighting efficient capital deployment even in a slow-growth environment. Assuming a cost of equity of 7.5% (given GIS's low beta and 10-year Treasury yields around 4.5%), and a 30% debt weighting, General Mills' weighted average cost of capital (WACC) would land around 6.8%. In other words, despite the recent headwinds, the company continues to create value for shareholders and allocate capital efficiently. That shows up in its dividend policy as well. General Mills currently offers a dividend yield of 4.4%, which is almost on par with the risk-free rate, all while maintaining a payout ratio of just 53%. Beyond General Mills' ability to generate returns above its cost of capital, the stock also appears attractively priced based on valuation. One particularly useful—and often underappreciated—metric for evaluating mature, capital-intensive companies like those in the consumer packaged goods sector is earnings yield, calculated as operating income divided by enterprise value. Over the past twelve months, General Mills reported $3.6 billion in operating income (EBIT) against an enterprise value of $43.5 billion, resulting in an earnings yield of 8.4%. Compared to a weighted average cost of capital (WACC) of 6.8%, this positive spread suggests the company is generating real value for shareholders—a potentially encouraging sign for long-term investors. However, the reliability of earnings yield as a valuation signal rests on the assumption that earnings will remain stable or improve. In General Mills' case, that assumption is under strain. The company recently lowered its fiscal 2025 guidance, now forecasting a 7% to 8% decline in adjusted operating profit, nearly twice the size of its earlier projections. In short, while the current valuation offers a degree of margin of safety, the growing uncertainty around future profitability raises meaningful concerns and tempers a more bullish outlook. Analyst sentiment on General Mills (GIS) remains mixed. Of the 13 analysts covering the stock, only one holds a bullish rating, ten are neutral, and one is bearish. The consensus stock price target for GIS stock is $57.67, representing an upside of approximately 6.7% over the coming year. General Mills checks many of the boxes for a classic value investment, consistently generating returns above its cost of capital while trading at what appears to be an attractive valuation. However, the company is contending with mounting structural headwinds—including evolving consumer eating habits, the rise of GLP-1 drugs, shifting retail dynamics, and increased competition from private-label brands. These challenges cast doubt on the long-term sustainability of its value creation, despite current metrics remaining solid. Given these concerns, General Mills currently leans more toward a value trap than a compelling value opportunity. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Johnson Controls Announces $9 Billion Increase to Share Repurchase Program
CORK, Ireland, June 13, 2025 /PRNewswire/ -- The board of directors of Johnson Controls International plc (NYSE: JCI), the global leader in smart, healthy and sustainable buildings, has approved a $9 billion share repurchase authorization, adding to the $1.1 billion remaining as of the end of the second fiscal quarter under the share repurchase authorization previously approved in 2021. In implementing share repurchases, Johnson Controls may purchase shares in the open market or through a variety of methods as permitted by applicable securities laws and other legal requirements, including through the use of a Rule 10b5-1 plan, a tender offer or an accelerated share repurchase program or any combination of the foregoing. There exists no obligation under the share repurchase authorization to repurchase any particular amount of shares within any timeframe, and the manner, timing and amount of any purchase will be determined subject to an evaluation of the price of Johnson Controls' shares, general market conditions and other factors. Johnson Controls' authorization to repurchase shares does not have a set expiration date and may be amended, suspended or terminated at any time at Johnson Controls' discretion without prior notice. Johnson Controls currently expects to effect repurchases as redemptions pursuant to Article 3(d) of its Articles of Association. About Johnson ControlsAt Johnson Controls (NYSE:JCI), we transform the environments where people live, work, learn and play. As the global leader in smart, healthy and sustainable buildings, our mission is to reimagine the performance of buildings to serve people, places and the planet. Building on a proud history of nearly 140 years of innovation, we deliver the blueprint of the future for industries such as healthcare, schools, data centers, airports, stadiums, manufacturing and beyond through OpenBlue, our comprehensive digital offering. Today, with a global team of experts, Johnson Controls offers the world's largest portfolio of building technology and software as well as service solutions from some of the most trusted names in the industry. Visit for more information and follow @Johnsoncontrols on social platforms. INVESTOR CONTACT: MEDIA CONTACT:Jim Lucas Danielle CanzanellaDirect: +1 414.340.1752 Direct: +1 203.499.8297Email: Email: CONTROLS INTERNATIONAL PLC CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Johnson Controls International plc ("Johnson Controls") has made statements in this communication that are forward-looking and therefore are subject to risks and uncertainties. All statements in this communication other than statements of historical fact are, or could be, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In this communication, statements regarding Johnson Controls' future share repurchase activity are forward-looking statements. Words such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "should," "forecast," "project" or "plan" and terms of similar meaning are also generally intended to identify forward-looking statements. However, the absence of these words does not mean that a statement is not forward-looking. Johnson Controls cautions that these statements are subject to numerous important risks, uncertainties, assumptions and other factors, some of which are beyond its control, that could cause its actual results to differ materially from those expressed or implied by such forward-looking statements, including, among others, risks related to: Johnson Controls' ability to manage macroeconomic and geopolitical volatility, including changes to laws or policies governing foreign trade, including tariffs, economic sanctions, foreign exchange and capital controls, import/export controls or other trade restrictions as well as supply chain disruptions; the ability of Johnson Controls to manage general economic, business and capital market conditions, including the impacts of trade restrictions, recessions, economic downturns and global price inflation; Johnson Controls' ability to develop or acquire new products and technologies that achieve market acceptance and meet applicable quality and regulatory requirements; the ability of Johnson Controls to execute on its operating model and drive organizational improvement; Johnson Controls' ability to successfully execute and complete portfolio simplification, including the completion of the divestiture of the Residential and Light Commercial business, as well as the possibility that the expected benefits of such actions will not be realized or will not be realized within the expected time frame; the ability to hire and retain senior management and other key personnel, including successfully completing Johnson Controls' Chief Executive Officer transition; the ability to innovate and adapt to emerging technologies, ideas and trends in the marketplace, including the incorporation of technologies such as artificial intelligence; fluctuations in the cost and availability of public and private financing for Johnson Controls' customers; the ability to manage disruptions caused by international conflicts, including Russia and Ukraine and the ongoing conflicts in the Middle East; managing the risks and impacts of potential and actual security breaches, cyberattacks, privacy breaches or data breaches, maintaining and improving the capacity, reliability and security of Johnson Controls' enterprise information technology infrastructure; the ability to manage the lifecycle cybersecurity risk in the development, deployment and operation of Johnson Controls' digital platforms and services; fluctuations in currency exchange rates; changes or uncertainty in laws, regulations, rates, policies, or interpretations that impact Johnson Controls' business operations or tax status; the ability to adapt to global climate change, climate change regulation and successfully meet Johnson Controls' public sustainability commitments; the outcome of litigation and governmental proceedings; the risk of infringement or expiration of intellectual property rights; Johnson Controls' ability to manage disruptions caused by catastrophic or geopolitical events, such as natural disasters, armed conflict, political change, climate change, pandemics and outbreaks of contagious diseases and other adverse public health developments; any delay or inability of Johnson Controls to realize the expected benefits and synergies of recent portfolio transactions; the tax treatment of recent portfolio transactions; significant transaction costs and/or unknown liabilities associated with such transactions; labor shortages, work stoppages, union negotiations, labor disputes and other matters associated with the labor force; and the cancellation of or changes to commercial arrangements. A detailed discussion of risks related to Johnson Controls' business is included in the section entitled "Risk Factors" in Johnson Controls Annual Report on Form 10-K for the fiscal year ended September 30, 2024 filed with the SEC on November 19, 2024, which is available at and under the "Investors" tab. The description of certain of these risks is supplemented in Item 1A of Part II of Johnson Controls subsequently filed Quarterly Reports on Form 10-Q. Shareholders, potential investors and others should consider these factors in evaluating the forward-looking statements and should not place undue reliance on such statements. The forward-looking statements included in this communication are made only as of the date of this communication, unless otherwise specified, and, except as required by law, Johnson Controls assumes no obligation, and disclaims any obligation, to update such statements to reflect events or circumstances occurring after the date of this communication. View original content to download multimedia: SOURCE Johnson Controls International plc Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
